Moderna FY2028 EPS Lowered by Brookline Capital Markets

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Brookline Capital Markets reduced their FY2028 earnings per share (EPS) estimates for shares of Moderna in a report issued on Friday, July 31st. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $0.53 per share for the year, down from their prior forecast of $0.68. The consensus estimate for Moderna’s current full-year earnings is ($6.41) per share. Brookline Capital Markets also issued estimates for Moderna’s FY2029 earnings at $11.69 EPS and FY2030 earnings at $19.27 EPS.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same quarter last year, the firm posted ($2.13) earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis.

Several other research firms also recently issued reports on MRNA. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Citigroup upped their price objective on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday. Royal Bank Of Canada raised their target price on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Morgan Stanley lifted their target price on Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 8th. Finally, The Goldman Sachs Group boosted their price target on Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $42.13.

Moderna Price Performance

Shares of MRNA stock opened at $55.14 on Monday. The company has a market capitalization of $21.88 billion, a PE ratio of -6.90 and a beta of 0.91. The firm has a fifty day simple moving average of $59.54 and a 200-day simple moving average of $52.75. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna has a twelve month low of $22.28 and a twelve month high of $85.60.

Hedge Funds Weigh In On Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. Capital World Investors acquired a new position in shares of Moderna during the fourth quarter worth approximately $378,299,000. Alyeska Investment Group L.P. bought a new position in Moderna during the fourth quarter valued at about $95,209,000. Norges Bank acquired a new position in shares of Moderna in the 4th quarter worth approximately $79,707,000. Invesco Ltd. grew its stake in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Moderna by 123.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock worth $52,775,000 after purchasing an additional 987,312 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 119,406 shares of company stock worth $5,928,762 in the last ninety days. 10.80% of the stock is owned by insiders.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.